Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 2
2020 4
2021 3
2022 1
2023 2
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements.
Zhang SM, Cai WL, Liu X, Thakral D, Luo J, Chan LH, McGeary MK, Song E, Blenman KRM, Micevic G, Jessel S, Zhang Y, Yin M, Booth CJ, Jilaveanu LB, Damsky W, Sznol M, Kluger HM, Iwasaki A, Bosenberg MW, Yan Q. Zhang SM, et al. Among authors: mcgeary mk. Nature. 2021 Oct;598(7882):682-687. doi: 10.1038/s41586-021-03994-2. Epub 2021 Oct 20. Nature. 2021. PMID: 34671158 Free PMC article.
IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy.
Zhou T, Damsky W, Weizman OE, McGeary MK, Hartmann KP, Rosen CE, Fischer S, Jackson R, Flavell RA, Wang J, Sanmamed MF, Bosenberg MW, Ring AM. Zhou T, et al. Among authors: mcgeary mk. Nature. 2020 Jul;583(7817):609-614. doi: 10.1038/s41586-020-2422-6. Epub 2020 Jun 24. Nature. 2020. PMID: 32581358 Free PMC article.
Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance.
Krykbaeva I, Bridges K, Damsky W, Pizzurro GA, Alexander AF, McGeary MK, Park K, Muthusamy V, Eyles J, Luheshi N, Turner N, Weiss SA, Olino K, Kaech SM, Kluger HM, Miller-Jensen K, Bosenberg M. Krykbaeva I, et al. Among authors: mcgeary mk. Cancer Immunol Res. 2023 Oct 4;11(10):1332-1350. doi: 10.1158/2326-6066.CIR-22-0699. Cancer Immunol Res. 2023. PMID: 37478171
Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis.
Damsky W, Wang A, Kim DJ, Young BD, Singh K, Murphy MJ, Daccache J, Clark A, Ayasun R, Ryu C, McGeary MK, Odell ID, Fazzone-Chettiar R, Pucar D, Homer R, Gulati M, Miller EJ, Bosenberg M, Flavell RA, King B. Damsky W, et al. Among authors: mcgeary mk. Nat Commun. 2022 Jun 6;13(1):3140. doi: 10.1038/s41467-022-30615-x. Nat Commun. 2022. PMID: 35668129 Free PMC article. Clinical Trial.
Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma.
McGeary MK, Damsky W, Daniels AJ, Lang SM, Xu Q, Song E, Huet-Calderwood C, Lou HJ, Paradkar S, Micevic G, Kaech SM, Calderwood DA, Turk BE, Yan Q, Iwasaki A, Bosenberg MW. McGeary MK, et al. Cancer Immunol Res. 2025 Feb 3;13(2):245-257. doi: 10.1158/2326-6066.CIR-23-0514. Cancer Immunol Res. 2025. PMID: 39589394
Setdb1 -loss induces type-I interferons and immune clearance of melanoma.
McGeary MK, Damsky W, Daniels A, Song E, Micevic G, Huet-Calderwood C, Lou HJ, Paradkar S, Kaech S, Calderwood DA, Turk BE, Iwasaki A, Bosenberg MW. McGeary MK, et al. bioRxiv [Preprint]. 2023 May 24:2023.05.23.541922. doi: 10.1101/2023.05.23.541922. bioRxiv. 2023. Update in: Cancer Immunol Res. 2025 Feb 03;13(2):245-257. doi: 10.1158/2326-6066.CIR-23-0514. PMID: 37292991 Free PMC article. Updated. Preprint.
KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations.
Liu X, Zhang SM, McGeary MK, Krykbaeva I, Lai L, Jansen DJ, Kales SC, Simeonov A, Hall MD, Kelly DP, Bosenberg MW, Yan Q. Liu X, et al. Among authors: mcgeary mk. Mol Cancer Ther. 2019 Mar;18(3):706-717. doi: 10.1158/1535-7163.MCT-18-0395. Epub 2018 Dec 6. Mol Cancer Ther. 2019. PMID: 30523048 Free PMC article.
11 results